文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

米多君对比安慰剂对重症监护室持续低血压患者血管加压药停用时间的影响(MIDAS):一项国际随机临床试验

Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.
PubMed 文献 · Intensive Care Med · 2020-09-03
一句话结论在需要单药静脉血管加压药的ICU低血压患者中,口服米多君20 mg每8小时一次未缩短血管加压药停用时间,且心动过缓更常见。

MIDAS是一项在美澳3家三级转诊医院开展的多中心随机对照试验,纳入需要单药静脉血管加压药≥24小时的成人低血压患者,随机接受口服米多君20 mg或安慰剂每8小时一次直至停用静脉血管加压药、ICU出院或发生不良事件。主要终点血管加压药停用时间在米多君组与安慰剂组无差异(中位23.5 vs 22.5小时,差值1小时,95%CI -10.4至12.3小时,p=0.62),次要终点亦无差异。米多君组给药后心动过缓发生率更高(7.6% vs 0%,p=0.02)。作者结论认为米多君未能加速脱离静脉血管加压药,对重症患者的低血压无效。

要点

  • 在需要单药静脉血管加压药≥24小时的ICU成人低血压患者中,口服米多君20 mg每8小时一次未缩短血管加压药停用时间(中位23.5 vs 22.5小时,差值1小时,95%CI -10.4至12.3小时,p=0.62)。
  • 米多君组与安慰剂组在ICU出院准备时间、ICU住院时长、医院住院时长及ICU再入院率等次要终点上均无差异。
  • 米多君组给药后心动过缓发生率高于安慰剂组(5例[7.6%] vs 0例[0%],p=0.02)。
  • 作者结论认为米多君未能加速脱离静脉血管加压药,对重症患者的低血压无效。

适用人群与场景

  • 美国与澳大利亚3家三级转诊医院中需要单药静脉血管加压药≥24小时的成人低血压患者。

处置流程与药物剂量

  • 口服米多君20 mg或安慰剂每8小时一次,在标准治疗基础上给予,直至停用静脉血管加压药、ICU出院或发生不良事件。

研究设计与关键结果

  • 多中心随机对照试验,2012年10月至2019年6月随机136例,132例接受分配干预并纳入改良意向性分析。
  • 主要终点血管加压药停用时间:米多君组中位23.5小时(IQR 10-54)vs 安慰剂组22.5小时(IQR 10.4-40),差值1小时,95%CI -10.4至12.3小时,p=0.62。
  • 次要终点(ICU出院准备时间、ICU住院时长、医院住院时长、ICU再入院率)均无差异。
  • 不良事件:心动过缓在米多君给药后更常见(5例[7.6%] vs 0例[0%],p=0.02)。

证据类型、等级与局限

  • 证据类型:国际多中心随机对照试验(MIDAS)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为米多君未能加速脱离静脉血管加压药,对重症患者的低血压无效;在需要单药静脉血管加压药≥24小时的ICU成人患者中,口服米多君20 mg每8小时一次未缩短血管加压药停用时间。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: ICU discharge is often delayed by a requirement for intravenous vasopressor medications to maintain normotension. We hypothesised that the administration of midodrine, an oral α1-adrenergic agonist, as adjunct to standard treatment shortens the duration of intravenous vasopressor requirement.

METHODS: In this multicentre, randomised, controlled trial including three tertiary referral hospitals in the US and Australia, we enrolled adult patients with hypotension requiring a single-agent intravenous vasopressor for ≥ 24 h. Subjects received oral midodrine (20 mg) or placebo every 8 h in addition to standard care until cessation of intravenous vasopressors, ICU discharge, or occurrence of adverse events. The primary outcome was time to vasopressor discontinuation. Secondary outcomes included time to ICU discharge readiness, ICU and hospital lengths of stay, and ICU readmission rates.

RESULTS: Between October 2012 and June 2019, 136 participants were randomised, of whom 132 received the allocated intervention and were included in the analysis (modified intention-to-treat approach). Time to vasopressor discontinuation was not different between midodrine and placebo groups (median [IQR], 23.5 [10-54] vs 22.5 [10.4-40] h; difference, 1 h; 95% CI - 10.4 to 12.3 h; p = 0.62). No differences in secondary endpoints were observed. Bradycardia occurred more often after midodrine administration (5 [7.6%] vs 0 [0%], p = 0.02).

CONCLUSION: Midodrine did not accelerate liberation from intravenous vasopressors and was not effective for the treatment of hypotension in critically ill patients.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Santer P, Anstey MH, Patrocínio MD, et al. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. Intensive Care Med. 2020. PMID: 32885276. doi:10.1007/s00134-020-06216-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。